Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Brainsway Ltd. Sponsored ADR (BWAY : NSDQ)

• Company Description    BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company's proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. Number of Employees: 120

• Price / Volume Information    Yesterday's Closing Price: $14.78 Daily Weekly Monthly 20 Day Moving Average: 69,145 shares Shares Outstanding: 19.56 (millions) Market Capitalization: $289.08 (millions) Beta: 1.22 52 Week High: $17.92 52 Week Low: $7.84 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.21% -7.59% 12 Week -7.04% -9.17% Year To Date 56.73% 39.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16 HARTUM STREET RAD TOWER 14TH FLOOR HAR HAHOTZVIM - JERUSALEM,L3 9777516 ISR ph: 972-2582-4030 fax: - ir@brainsway.com http://www.brainsway.com

• General Corporate Information    Officers Hadar Levy - Chief Executive Officer Ami Boehm - Chairman of the Board Ido Marom - Chief Financial Officer Avner Hagai - Director Eti Mitrany - Director Peer Information Brainsway Ltd. Sponsored ADR (BJCT) Brainsway Ltd. Sponsored ADR (CADMQ) Brainsway Ltd. Sponsored ADR (APNO) Brainsway Ltd. Sponsored ADR (UPDC) Brainsway Ltd. Sponsored ADR (IMTIQ) Brainsway Ltd. Sponsored ADR (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 10501L106 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 19.56 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $289.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.33 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: 44.34 Trailing 12 Months: 49.27 PEG Ratio: - Price Ratios Price/Book: 4.01 Price/Cash Flow: 59.27 Price / Sales: 5.89 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -20.00% Sales Growth vs. Year Ago Period: 28.66% vs. Previous Quarter: 6.97% ROE 09/30/25 - 9.46 06/30/25 - 8.97 03/31/25 - 7.35 ROA 09/30/25 - 5.96 06/30/25 - 5.65 03/31/25 - 4.72 Current Ratio 09/30/25 - 3.19 06/30/25 - 3.51 03/31/25 - 5.03 Quick Ratio 09/30/25 - 3.02 06/30/25 - 3.34 03/31/25 - 4.75 Operating Margin 09/30/25 - 12.73 06/30/25 - 11.60 03/31/25 - 9.01 Net Margin 09/30/25 - 12.73 06/30/25 - 11.60 03/31/25 - 9.01 Pre-Tax Margin 09/30/25 - 14.06 06/30/25 - 12.66 03/31/25 - 10.22 Book Value 09/30/25 - 3.58 06/30/25 - 3.61 03/31/25 - 3.38 Inventory Turnover 09/30/25 - 2.78 06/30/25 - 2.77 03/31/25 - 2.68 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©